Abbott (NYSE:ABT) held on to a win in its patent infringement war with Johnson & Johnson‘s (NYSE:JNJ) Cordis Corp. after a federal appeals court upheld a lower court ruling last month.
Stent Wars
MassDevice.com +3 | The top 3 med-tech stories for March 15, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Abbott accuses Boston Scientific of poaching stent sales VP, reps
OrbusNeich takes Boston Scientific patent row to Ireland
OrbusNeich continued its global row against medtech titan Boston Scientific (NYSE:BSX) even further, filing a patent infringement lawsuit in Ireland to join ones pending in Germany and the Netherlands.
Legal: Boston Scientific notches a win in Cordis stent patent spat
A federal appeals court upheld a $41 million verdict for Boston Scientific over erstwhile arch-rival Cordis Corp., the Johnson & Johnson subsidiary that ceded the coronary stent market in 2011.
Legal: OrbusNeich takes Boston Scientific patent row to Germany, the Netherlands
OrbusNeich is taking a recent patent infringement win against Boston Scientific (NYSE:BSX) even further, filing lawsuits in both Germany and the Netherlands to allege patent infringement over stent technology.
UPDATE: OrbusNeich claims European stent patent win over Boston Scientific
UPDATED Feb. 13, 2012 with comment from Boston Scientific.
OrbusNeich claimed a win over Boston Scientific (NYSE:BSX) in a European patent battle over stent technology.
Boston Scientific launches Promus Premier stent in Europe
Boston Scientific (NYSE:BSX) said it plans to immediately launch its Promus Premier drug-eluting stent across the pond, now that the European Union has given the device CE Mark approval.
Svelte Medical launches drug-eluting stent trial
Svelte Medical said it launched the Direct II Phase II clinical trial of its drug-eluting stent comparing the device with Medtronic‘s (NYSE:MDT) Resolute DES.
The Svelte device elutes the anti-stenosis drug sirolimus using a bioabsorbable carrier made of amino acids, unlike the polymer-based drug carrier used in the Resolute stent.